Literature DB >> 21519241

Role of microRNAs in lymphoid biology and disease.

Muller Fabbri1, Carlo M Croce.   

Abstract

PURPOSE OF REVIEW: This review provides a state-of-the-art knowledge on the implications of microRNA (miRNA) dysregulation in lymphoid malignancies. RECENT
FINDINGS: Several new studies have broadened our understanding of how aberrations of the miRNome contribute to the development of a malignant lymphoid phenotype. Recently, a new pathogenetic model involving miRNAs and protein coding genes (such as TP53 and ZAP-70) has been identified and explains the prognostic implications of the most recurrent chromosomal abnormalities in human B-cell chronic lymphocytic leukemia. Moreover, new recent studies have addressed the role of miRNAs in human lymphomas and acute lymphoblastic leukemias.
SUMMARY: The recent advances in our understanding of the role of miRNAs in lymphoid malignancies demonstrate that miRNAs can effectively be used as tumoral biomarkers with implications for diagnosis, prognosis, and prediction of response to therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21519241      PMCID: PMC3400499          DOI: 10.1097/MOH.0b013e3283476012

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  67 in total

Review 1.  Mechanisms of control of microRNA biogenesis.

Authors:  Brandi N Davis-Dusenbery; Akiko Hata
Journal:  J Biochem       Date:  2010-09-09       Impact factor: 3.387

2.  Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma.

Authors:  Alfons Navarro; Tania Diaz; Antonio Martinez; Anna Gaya; Aina Pons; Bernat Gel; Carles Codony; Gerardo Ferrer; Carmen Martinez; Emili Montserrat; Mariano Monzo
Journal:  Blood       Date:  2009-08-07       Impact factor: 22.113

3.  OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma.

Authors:  Pedro P Medina; Mona Nolde; Frank J Slack
Journal:  Nature       Date:  2010-08-08       Impact factor: 49.962

4.  Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia.

Authors:  Shuangli Mi; Zejuan Li; Ping Chen; Chunjiang He; Donglin Cao; Abdel Elkahloun; Jun Lu; Luis A Pelloso; Mark Wunderlich; Hao Huang; Roger T Luo; Miao Sun; Miao He; Mary Beth Neilly; Nancy J Zeleznik-Le; Michael J Thirman; James C Mulloy; Paul P Liu; Janet D Rowley; Jianjun Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-02       Impact factor: 11.205

5.  Comparison of miRNA profiles of microdissected Hodgkin/Reed-Sternberg cells and Hodgkin cell lines versus CD77+ B-cells reveals a distinct subset of differentially expressed miRNAs.

Authors:  Pieter Van Vlierberghe; An De Weer; Pieter Mestdagh; Tom Feys; Katleen De Preter; Pascale De Paepe; Kathleen Lambein; Jo Vandesompele; Nadine Van Roy; Bruno Verhasselt; Bruce Poppe; Frank Speleman
Journal:  Br J Haematol       Date:  2009-09-22       Impact factor: 6.998

Review 6.  Causes and consequences of microRNA dysregulation in cancer.

Authors:  Carlo M Croce
Journal:  Nat Rev Genet       Date:  2009-10       Impact factor: 53.242

7.  Karyotype-specific microRNA signature in chronic lymphocytic leukemia.

Authors:  Rosa Visone; Laura Z Rassenti; Angelo Veronese; Cristian Taccioli; Stefan Costinean; Baltazar D Aguda; Stefano Volinia; Manuela Ferracin; Jeff Palatini; Veronica Balatti; Hansjuerg Alder; Massimo Negrini; Thomas J Kipps; Carlo M Croce
Journal:  Blood       Date:  2009-08-28       Impact factor: 22.113

8.  The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia.

Authors:  Ulf Klein; Marie Lia; Marta Crespo; Rachael Siegel; Qiong Shen; Tongwei Mo; Alberto Ambesi-Impiombato; Andrea Califano; Anna Migliazza; Govind Bhagat; Riccardo Dalla-Favera
Journal:  Cancer Cell       Date:  2010-01-07       Impact factor: 31.743

9.  Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice.

Authors:  Stefan Costinean; Sukhinder K Sandhu; Irene M Pedersen; Esmerina Tili; Rossana Trotta; Danilo Perrotti; David Ciarlariello; Paolo Neviani; Jason Harb; Lauren Rachel Kauffman; Aaditya Shidham; Carlo Maria Croce
Journal:  Blood       Date:  2009-06-11       Impact factor: 22.113

10.  MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia.

Authors:  Hua Zhang; Xue-Qun Luo; Peng Zhang; Li-Bin Huang; Yu-Sheng Zheng; Jun Wu; Hui Zhou; Liang-Hu Qu; Ling Xu; Yue-Qin Chen
Journal:  PLoS One       Date:  2009-11-13       Impact factor: 3.240

View more
  23 in total

1.  The High Expression of the microRNA 17-92 Cluster and its Paralogs, and the Downregulation of the Target Gene PTEN, Is Associated with Primary Cutaneous B-Cell Lymphoma Progression.

Authors:  Maxime Battistella; Martha Romero; Luis-Jaime Castro-Vega; Guillaume Gapihan; Fatiha Bouhidel; Martine Bagot; Jean-Paul Feugeas; Anne Janin
Journal:  J Invest Dermatol       Date:  2015-01-29       Impact factor: 8.551

2.  Genomic imbalances and microRNA transcriptional profiles in patients with mycosis fungoides.

Authors:  Fuad Huaman Garaicoa; Alejandro Roisman; Mariana Arias; Carla Trila; Miguel Fridmanis; Alejandra Abeldaño; Silvia Vanzulli; Marina Narbaitz; Irma Slavutsky
Journal:  Tumour Biol       Date:  2016-07-29

3.  Alpha-2, 3-sialyltransferases regulate the multidrug resistance of chronic myeloid leukemia through miR-4701-5p targeting ST3GAL1.

Authors:  Yan Li; Shihua Luo; Weijie Dong; Xiaobo Song; Huimin Zhou; Lifen Zhao; Li Jia
Journal:  Lab Invest       Date:  2016-04-18       Impact factor: 5.662

4.  Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.

Authors:  Xinwei Zhang; Xiaohong Zhao; Warren Fiskus; Jianhong Lin; Tint Lwin; Rekha Rao; Yizhuo Zhang; John C Chan; Kai Fu; Victor E Marquez; Selina Chen-Kiang; Lynn C Moscinski; Edward Seto; William S Dalton; Kenneth L Wright; Eduardo Sotomayor; Kapil Bhalla; Jianguo Tao
Journal:  Cancer Cell       Date:  2012-10-16       Impact factor: 31.743

Review 5.  MicroRNA biomarkers in glioblastoma.

Authors:  Simon Kjær Hermansen; Bjarne Winther Kristensen
Journal:  J Neurooncol       Date:  2013-05-23       Impact factor: 4.130

6.  Oncogenic microRNA-155 and its target PU.1: an integrative gene expression study in six of the most prevalent lymphomas.

Authors:  Hana Huskova; Katarina Korecka; Josef Karban; Jarmila Vargova; Karina Vargova; Nina Dusilkova; Marek Trneny; Tomas Stopka
Journal:  Int J Hematol       Date:  2015-08-11       Impact factor: 2.490

7.  miR-137 regulates the constitutive androstane receptor and modulates doxorubicin sensitivity in parental and doxorubicin-resistant neuroblastoma cells.

Authors:  A A Takwi; Y-M Wang; J Wu; M Michaelis; J Cinatl; T Chen
Journal:  Oncogene       Date:  2013-08-12       Impact factor: 9.867

8.  MiR-132-3p serves as a tumor suppressor in mantle cell lymphoma via directly targeting SOX11.

Authors:  Baoyu Wu; Jingyu Li; Han Wang; Qian Wu; Hui Liu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-02-10       Impact factor: 3.000

9.  microRNA expression profiles identify subtypes of mantle cell lymphoma with different clinicobiological characteristics.

Authors:  Alba Navarro; Guillem Clot; Miriam Prieto; Cristina Royo; Maria Carmela Vegliante; Virginia Amador; Elena Hartmann; Itziar Salaverria; Sílvia Beà; Jose Ignacio Martín-Subero; Andreas Rosenwald; German Ott; Adrian Wiestner; Wyndham H Wilson; Elías Campo; Luis Hernández
Journal:  Clin Cancer Res       Date:  2013-05-02       Impact factor: 12.531

10.  miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer.

Authors:  Jing Sun; Xin Cai; Mingo Mh Yung; Wei Zhou; Jing Li; Yi Zhang; Zhuqing Li; Stephanie S Liu; Annie N Y Cheung; Hextan Y S Ngan; Yiliang Li; Zhijun Dai; Yan Kai; Alexandros Tzatsos; Weiqun Peng; David W Chan; Wenge Zhu
Journal:  Oncogene       Date:  2018-08-30       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.